Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Amaia Jauregi-Miguel *Wallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0003-0938-7734
Simon Söderholm *Wallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0001-5350-7102
Tamina Weiss *Wallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0009-0002-3605-0782
Anna Nordin *Wallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0002-5868-4797
Valeria Ghezzi *Wallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.
Salome M BrütschWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.
Pierfrancesco PagellaWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.
Yorick van de GriftWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0003-0920-9030
Gianluca ZambaniniWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0003-1275-6027
Jacopo UlisseWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0002-9371-9094
Alessandro MattiaWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0009-0004-9008-8372
Ruslan DeviatiiarovRegulatory Genomics Research Center, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Tatarstan 420012, Russian Federation.ORCID 0000-0003-0019-2076
Elena FaustiniWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0009-0007-8549-4933
Lavanya MoparthiWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.
Wenjing ZhongWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.
Bergthor BjörnssonDepartment of Surgery in Linköping, Linköping University, Linköping 58225, Sweden.
Per SandströmDepartment of Surgery in Linköping, Linköping University, Linköping 58225, Sweden.ORCID 0000-0002-8078-9528
Erik LundqvistDepartment of Biomedicine and Clinical Sciences, Linköping University, Linköping 58225, Sweden.ORCID 0000-0001-5312-1023
Francisca LottersbergerWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0002-0677-8986
Stefan KochWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.
Andreas E MoorDepartment of Biosystems Science and Engineering, Federal Institute of Technology Zürich, Basel 4056, Switzerland.ORCID 0000-0001-8715-8449
Xiao-Feng SunDepartment of Oncology, Division of Surgery, Orthopedics and Oncology, Faculty of Medicine and Health Sciences, Linköping University, Linköping 58225, Sweden.ORCID 0000-0001-5804-9374
Eleonore von CastelmurWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0001-7061-4890
Guojun ShengInternational Research Center for Medical Sciences, Kumamoto University, Kumamoto 860-8555, Japan.
Claudio CantùWallenberg Centre for Molecular Medicine, Linköping University, Linköping 58183, Sweden.ORCID 0000-0003-1547-5415
Funding
Additional Ventures (AV) SVRF2021-1048003Cancerfonden (Swedish Cancer Society) 21 1572 PjCancerfonden (Swedish Cancer Society) CAN 2018/542Joanna Cocozzas stiftelse for barnmedicinsk forskning 2023Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) 2018-2024MEXT | Japan Society for the Promotion of Science (JSPS) 2022Swedish Foundation for International Cooperation in Research and Higher Education (STINT) 2022Vetenskapsrådet (VR) 2021-03075Vetenskapsrådet (VR) 2023-01898
6 · The paper itself
Abstract
Wnt signaling orchestrates gene expression in a plethora of processes during development and adult cell homeostasis via the action of nuclear β-catenin. Yet, little is known about how β-catenin generates context-specific transcriptional outcomes. Understanding this will reveal how aberrant Wnt/β-catenin signaling causes neoplasia specifically of the colorectal epithelium. We have previously identified the transcription factor TBX3 as a tissue-specific component of the Wnt/β-catenin nuclear complex during mouse forelimb development. In this study, we show that TBX3 is functionally active in human colorectal cancer (CRC). Here, genome-wide binding and transcriptomics analyses reveal that TBX3 regulates cancer metastasis genes in cooperation with Wnt/β-catenin. Proteomics proximity labeling performed across Wnt pathway activation shows that TBX3 engages with several transcription factors and chromatin remodeling complexes found at Wnt responsive elements (WRE). Protein sequence and structure analysis of TBX3 revealed short motifs, including an exposed Asn-Pro-Phe (NPF), that mediate these interactions. Deletion of these motifs abrogates TBX3's proximity to its protein partners and its ability to enhance the Wnt-dependent transcription. TBX3 emerges as a key modulator of the oncogenic activity of Wnt/β-catenin in CRC, and its mechanism of action exposes protein-interaction surfaces as putative druggable targets.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The developmental factor TBX3 engages with the Wnt/β-catenin transcriptional complex in colorectal cancer to regulate metastasis genes. · full record | OpenQuestion